PriceTargets.com logo

RedHill Biopharma - RDHL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.35 As of 12/24/2024 06:19 PM ET
▲ +0.03 (0.47%)

This chart shows the closing price for RDHL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RedHill Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDHL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDHL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for RedHill Biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.35.

This chart shows the closing price for RDHL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in RedHill Biopharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2021BTIG ResearchLower TargetBuy$16,000.00 ➝ $10,000.00
10/13/2021HC WainwrightReiterated RatingBuy$21,000.00
9/24/2021HC WainwrightReiterated RatingBuy$21,000.00
9/15/2021BTIG ResearchLower TargetPositive ➝ Buy$24,000.00 ➝ $16,000.00
9/14/2021HC WainwrightLower TargetBuy$23,000.00 ➝ $21,000.00
8/31/2021Cantor FitzgeraldInitiated CoverageOverweight$22,000.00
8/30/2021HC WainwrightReiterated RatingBuy$23,000.00
8/24/2021HC WainwrightReiterated RatingBuy$23,000.00
7/21/2021HC WainwrightReiterated RatingBuy$23,000.00
7/14/2021HC WainwrightReiterated RatingBuy$23,000.00
6/29/2021HC WainwrightReiterated RatingBuy$23,000.00
6/1/2021Roth CapitalReiterated RatingBuy
6/1/2021HC WainwrightReiterated RatingBuy
5/31/2021BTIG ResearchReiterated RatingBuy$26,000.00
5/28/2021WBB SecuritiesDowngradeStrong-Buy ➝ Buy$17,000.00 ➝ $16,000.00
5/18/2021HC WainwrightInitiated CoverageBuy$23,000.00
11/12/2020Roth CapitalLower TargetBuy$16,000.00 ➝ $12,000.00
10/13/2020Ascendiant Capital MarketsReiterated RatingBuy$22,000.00
9/11/2020BTIG ResearchInitiated CoverageBuy$26,000.00
3/5/2020HC WainwrightReiterated RatingBuy$18,000.00 ➝ $14,000.00
2/27/2020Roth CapitalLower Target$20,250.00 ➝ $15,000.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
RedHill Biopharma logo
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $6.35
Low: $6.35
High: $6.69

50 Day Range

MA: $7.63
Low: $6.32
High: $8.78

52 Week Range

Now: $6.35
Low: $6.00
High: $40.50

Volume

15,212 shs

Average Volume

103,921 shs

Market Capitalization

$8.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.65

Frequently Asked Questions

What sell-side analysts currently cover shares of RedHill Biopharma?

The following Wall Street analysts have issued stock ratings on RedHill Biopharma in the last year: StockNews.com.
View the latest analyst ratings for RDHL.

What is the current price target for RedHill Biopharma?

0 Wall Street analysts have set twelve-month price targets for RedHill Biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for RedHill Biopharma in the next year.
View the latest price targets for RDHL.

What is the current consensus analyst rating for RedHill Biopharma?

RedHill Biopharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RDHL.

What other companies compete with RedHill Biopharma?

Other companies that are similar to RedHill Biopharma include Verrica Pharmaceuticals, Anebulo Pharmaceuticals, BioAtla, Marker Therapeutics and RenovoRx. Learn More about companies similar to RedHill Biopharma.

How do I contact RedHill Biopharma's investor relations team?

RedHill Biopharma's physical mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company's listed phone number is 972-3541-3131 and its investor relations email address is [email protected]. The official website for RedHill Biopharma is www.redhillbio.com. Learn More about contacing RedHill Biopharma investor relations.